Ghost Tree Capital’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Ghost Tree Capital’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-100,000	Closed	-$2.01M	–	78
2023 Q3	$2.01M	Hold	100,000	–	–	0.66%	49
2023 Q2	$2.82M	Buy	+100,000	New	+$2.4M	0.93%	28
2022 Q2	–	Sell	-80,000	Closed	-$3.69M	–	47
2022 Q1	$3.69M	Hold	80,000	–	–	0.8%	25
2021 Q4	$6.72M	Buy	80,000 +15,000	+23%	+$1.16M	2.41%	14
2021 Q3	$4.33M	Buy	+65,000	New	+$3.75M	1.27%	30

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Ghost Tree Capital's ZNTL Position: Q4 2023 in Review

Ghost Tree Capital sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2023, closing a stake of 100,000 shares — an estimated $2.01M sold.

Ghost Tree Capital first reported a position in ZNTL in Q3 2021 and held it in 5 quarters. The position peaked at $6.72M in Q4 2021. 120 funds tracked by Wall St. Rank hold ZNTL as of Q4 2023.

Ghost Tree Capital reported no remaining Zentalis Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Ghost Tree Capital sold 100,000 Zentalis Pharmaceuticals shares in Q4 2023, an estimated $2.01M.
Ghost Tree Capital first reported a position in Zentalis Pharmaceuticals in Q3 2021 and held it in 5 quarters.
Ghost Tree Capital's Zentalis Pharmaceuticals position peaked at $6.72M in Q4 2021.
120 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2023.

Based on Ghost Tree Capital's 13F filing for Q4 2023, filed 14 Feb 2024.